Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Hypertension

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/HJH.0b013e32835c1d1bPMID 23221987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab for retinopathy of prematurity.

  2012cited by this paper
• Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress

  2012influential reference
• Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1.

  2012cited by this paper
• Angiogenic balance and diagnosis of pre-eclampsia: selecting the right VEGF receptor

  2012cited by this paper
• Targeting the endothelin axis in prostate carcinoma

  2012cited by this paper
• Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

  2012cited by this paper
• Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

  2012cited by this paper
• Bevacizumab-Induced Hypertension

  2011cited by this paper
• The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

  2011influential reference
• Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.

  2011cited by this paper
• Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers

  2011cited by this paper
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cited by this paper
• Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

  2011cited by this paper
• PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)

  2011cited by this paper
• Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.

  2011cited by this paper
• Endothelin: key mediator of hypertension in preeclampsia.

  2011cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• Proteinuria and hypertension with tyrosine kinase inhibitors.

  2011cited by this paper
• Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

  2011cited by this paper
• Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

  2011cited by this paper
• Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

  2010cited by this paper
• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  2010cited by this paper
• Endothelin--biology and disease.

  2010cited by this paper
• Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant Rats

  2010cited by this paper
• Sorafenib: a clinical and pharmacologic review

  2010cited by this paper
• Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.

  2010cited by this paper
• Nephrotoxicities Associated with the Use of Tyrosine Kinase Inhibitors: A Single-Center Experience and Review of the Literature

  2010cited by this paper
• Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

  2010influential reference
• Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

  2010cited by this paper
• Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib

  2010cited by this paper
• Bevacizumab increases risk for severe proteinuria in cancer patients.

  2010cited by this paper
• Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

  2010cited by this paper
• Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

  2010cited by this paper
• Mononuclear Phagocyte System Depletion Blocks Interstitial Tonicity-Responsive Enhancer Binding Protein/Vascular Endothelial Growth Factor C Expression and Induces Salt-Sensitive Hypertension in Rats

  2010cited by this paper
• Glomerular Disturbances in Preeclampsia: Disruption Between Glomerular Endothelium and Podocyte Symbiosis

  2010cited by this paper
• High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity.

  2010cited by this paper
• Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats.

  2009cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

  2009influential reference
• Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

  2009cited by this paper
• Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors?

  2009influential reference
• Alteration of nitric oxide gas on gene expression of endothelin-1 and endothelial nitric oxide synthase by a time- and dose-dependent manner in human endothelial cells.

  2009cited by this paper
• Renal effects of anti-angiogenesis therapy: update for the internist.

  2009cited by this paper
• ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats

  2009cited by this paper
• Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

  2009cited by this paper
• Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

  2009cited by this paper
• Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects

  2009influential reference
• Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• Biomarkers of response and resistance to antiangiogenic therapy

  2009cited by this paper
• Management of hypertension in angiogenesis inhibitor-treated patients.

  2009cited by this paper
• An overview of small-molecule inhibitors of VEGFR signaling

  2009cited by this paper
• Plasma nitric oxide, endothelin‐1, arginase and superoxide dismutase in pre‐eclamptic women

  2008cited by this paper
• Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

  2008cited by this paper
• Nitric Oxide, Tetrahydrobiopterin, Oxidative Stress, and Endothelial Dysfunction in Hypertension

  2008cited by this paper
• Role of endothelin-1 in clinical hypertension: 20 years on.

  2008cited by this paper
• VEGF-targeted therapy: mechanisms of anti-tumour activity

  2008cited by this paper
• Preeclampsia pathogenesis: "triple a rating"-autoantibodies and antiangiogenic factors.

  2008cited by this paper
• Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

  2008cited by this paper
• Distinct modulation of the endothelin-1 pathway in iNOS-/- and eNOS-/- mice.

  2008cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  2008cited by this paper
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

  2008cited by this paper
• The endothelin axis in cancer.

  2008cited by this paper
• Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells.

  2008cited by this paper
• Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

  2008cited by this paper
• Autocrine VEGF signaling is required for vascular homeostasis.

  2007influential reference
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• Endothelin-1-induced signaling pathways in vascular smooth muscle cells.

  2007cited by this paper
• Nephrotic syndrome after bevacizumab: case report and literature review.

  2007cited by this paper
• Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

  2007cited by this paper
• 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.

  2007cited by this paper
• Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

  2007cited by this paper
• Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

  2007cited by this paper
• Thrombotic microangiopathy and anti-VEGF agents.

  2007cited by this paper
• Hypertension as a predictive factor of Sunitinib activity.

  2007cited by this paper
• Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

  2006cited by this paper
• Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Increased skin capillary density in treated essential hypertensive patients.

  2006cited by this paper
• Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy.

  2006cited by this paper
• Soluble endoglin contributes to the pathogenesis of preeclampsia

  2006cited by this paper
• Increased salt-sensitivity in endothelial nitric oxide synthase-knockout mice.

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• NEPH2 is located at the glomerular slit diaphragm, interacts with nephrin and is cleaved from podocytes by metalloproteinases.

  2005cited by this paper
• ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin

  2005cited by this paper
• ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.

  2005cited by this paper
• Circulating Angiogenic Factors and the Risk of Preeclampsia

  2005cited by this paper
• Plasma nitric oxide, endothelin‐1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

  2004cited by this paper
• Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*

  2003cited by this paper
• Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) could contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

  2003influential reference
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• Biogenesis and exocytosis of Weibel-Palade bodies

  2002cited by this paper

• Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in Chronic Kidney Disease.

  2026cites this paper
• A New Era of Biomarkers in Cardio-Oncology

  2026cites this paper
• Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer

  2025cites this paper
• Reviewing the path to balance: mechanisms and management of hypertension associated with targeting vascular endothelium in cancer therapy

  2025cites this paper
• Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies

  2024cites this paper
• Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

  2023cites this paper
• The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

  2022cites this paper
• Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

  2022cites this paper
• Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings.

  2022cites this paper
• Resistance to antiangiogenic treatments: A review

  2022cites this paper
• Onco-hypertension: Overview of hypertension with anti-cancer agents

  2021cites this paper
• Hypertension: Current trends and future perspectives

  2021cites this paper
• Sorafenib not only impairs endothelium-dependent relaxation but also promotes vasoconstriction through the upregulation of vasoconstrictive endothelin type B receptors.

  2021cites this paper
• Onco-hypertension: An Emerging Specialty.

  2021cites this paper
• Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension

  2021cites this paper
• Anlotinib-Induced Hypertension: Current Concepts and Future Prospects.

  2021cites this paper
• The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

  2021cites this paper
• Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions

  2020cites this paper
• CMAR_A_275624 11133..11143

  2020cites this paper
• Cardiotoxicity Evaluation of Tyrosine Kinase Inhibitors using Human Induced Pluripotent Stem Cell-derived Healthy and Long QT Syndrome Cardiomyocytes

  2020cites this paper
• Vascular toxicity associated with anti-angiogenic drugs.

  2020cites this paper
• Endothelin: 30 Years From Discovery to Therapy.

  2019cites this paper
• Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

  2019cites this paper
• Endothelins in cardiovascular biology and therapeutics

  2019cites this paper
• Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK

  2019cites this paper
• Endothelin receptor antagonism during preeclampsia: a matter of timing?

  2019cites this paper
• Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.

  2019cites this paper
• Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors

  2019cites this paper
• Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition

  2019cites this paper
• Changes in central and peripheral blood pressure parameters during antiangiogenic treatment of metastatic renal cell carcinoma.

  2019cites this paper
• Effects of ECE-1b rs213045 and rs2038089 polymorphisms on the development of contrast-induced acute kidney injury in patients with acute coronary syndrome

  2019cites this paper
• Transfer and Vascular Effect of Endothelin Receptor Antagonists in the Human Placenta

  2019cites this paper
• A case of focal segmental glomerulosclerosis inferred by bevacizumab

  2018cites this paper
• Tyrosine Kinase Inhibitor-Induced Hypertension

  2018cites this paper
• Risk factors for hypertensive retinopathy in a Chinese population with hypertension: The Beijing Eye study.

  2018cites this paper
• Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients.

  2018cites this paper
• Management of VEGF-Targeted Therapy-Induced Hypertension

  2018cites this paper
• Vascular damage and dysfunction in hypertensive emergencies

  2017cites this paper
• Bevacizumab‐induced hypertension: Clinical presentation and molecular understanding

  2017cites this paper
• Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism

  2017cites this paper
• Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney

  2017cites this paper
• Endothelin-1 and antiangiogenesis.

  2016cites this paper
• The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention

  2016influential citation
• Curative effects of enalapril combined with folic acid tablets on hypertension and its mechanism

  2016cites this paper
• Latest Results for Anti-Angiogenic Drugs in Cancer Treatment.

  2016cites this paper
• The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia

  2016cites this paper
• Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.

  2016cites this paper
• Hypertension and renal toxicity during angiogenesis inhibition : Salt dependency and treatment options

  2016cites this paper
• Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment

  2016cites this paper
• Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors

  2016cites this paper
• Plasma lactate and incident hypertension in the atherosclerosis risk in communities study.

  2015cites this paper
• Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events?

  2015cites this paper
• Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma

  2015cites this paper
• Endothelium-derived ET-1 and the development of renal injury.

  2015cites this paper
• Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib

  2015cites this paper
• Endothelin antagonism and hypertension: an evolving target.

  2015cites this paper
• Arterial hypertension induced by angiogenesis inhibitors

  2014cites this paper
• SFlt-1 Elevates Blood Pressure by Augmenting Endothelin-1-Mediated Vasoconstriction in Mice

  2014cites this paper
• Excess Maternal Glucocorticoids in Response to In Utero Undernutrition Inhibit Offspring Angiogenesis

  2014cites this paper
• Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib: Preclinical Study

  2014cites this paper
• Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.

  2014cites this paper
• The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation

  2014cites this paper
• Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.

  2013cites this paper
• Inhibitors of Angiogenesis and Blood Pressure

  2013cites this paper
• Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

  2013cites this paper